Complete Story


Medical Board's January Recap



The medical board is busy drafting rules to support the recently passed telemedicine legislation, Ohio Senate Bill 122. Currently, the board has several rules that contain provisions that include telehealth topics, but they do not have an overarching “telehealth” rule. At the board’s meeting on January 12, the board shared that they will be developing a specific telehealth rule and amending any rules that are impacted by the new law.

Notable provisions of the new telehealth law include:

Ohio’s new telehealth law goes into effect in March 2022.  It is unlikely that the medical board’s rule will be finalized by that time.  However, the new law allows the board to suspend its existing telehealth provisions until the board’s new/amended rules are finalized. OSMA will be actively following the rule’s progression and we will work with the medical board to provide physician feedback as the rule develops.

Medical Marijuana

The Medical Board received nine petitions for potential new qualifying conditions during the 2021 petition window. The Medical Board’s Medical Marijuana Committee is anticipated to meet February 9. At that meeting, the committee will decide which petitions will be considered. A final vote on new qualifying conditions is expected this summer.

Condition names as listed by the petitioners:

  1. Gilbert’s Disease
  2. Anxiety
  3. Degenerative Disk Disease, Chronic pain, PTSD
  4. Bi polar, Anxiety, Depression, Sleep Disorder
  5. Opioid Use Disorder (OUD)
  6. Insomnia
  7. Lupus
  8. Opioid Use Disorder
  9. Autism Spectrum Disorder

Prescribing Controlled Substances for Weight Loss

At the meeting of the Board in October 2021, the Board voted to move forward with changes to Rules 4731-11-04 and 04.1, to develop a rule draft that allows for the continued use of phentermine, a Schedule IV controlled substance for weight loss with rule requirements that prevent overprescribing, abuse and diversion.

At the board’s January 2022 meeting, the board introduced a proposed rule that would eliminate the 12-week prescribing limit and the requirement to strictly follow the FDA labeling requirements. The proposed rule would allow physician assistants to prescribe, combine the short term and chronic weight management rules, allow for flexibility for telehealth visits, and add some interim requirements when the prescribing extends past 3 months.

OSMA has been working with a group of national and local obesity medicine experts on this issue for several years.  The medical experts are currently reviewing the draft rule and will work with the OSMA to provide stakeholder feedback when it is requested.


In your inbox 

Printer-Friendly Version